• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Cardiovascular
  • A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine

Disease
cardiovascular system
Drug Name
Brilinta
Generic Name
Ticagrelor
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
I
Start Date
Jan 17, 2012
ClinicalTrials.gov ID
NCT01504906
Recruiting Status
Closed
Protocol Status
Not Available
Report
Nov 6, 2012
  • D5130C00074.pdf (114 KB)

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013